A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT ID: NCT06095115

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

684 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-12

Study Completion Date

2027-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JNJ-77242113

Adolescent and adult participants will receive JNJ-77242113 from Week 0 through Week 156. At Week 24, adult participants who are psoriasis area and severity index (PASI) 75 or investigator global assessment (IGA) score of 0 or 1 responders (that is, those who achieve an IGA score of 0 or 1 and have \>=2-grade improvement from baseline) will be re-randomized either to continue JNJ-77242113 or to placebo (and will be retreated with JNJ-77242113 upon loss of \>=50% of their Week 24 PASI improvement). Adult participants identified as both PASI 75 and IGA 0 or 1 score non-responders will continue to receive JNJ-77242113 through Week 52. From Week 52 to Week 156, all adult participants will receive JNJ-77242113. Adolescents will not participate in re-randomization regardless of their PASI score or IGA score at Week 24. Adolescents will continue to receive JNJ-77242113 from Week 0 through Week 156.

Group Type EXPERIMENTAL

JNJ-77242113

Intervention Type DRUG

JNJ-77242113 will be administered orally.

Placebo

Adolescent and adult participants will receive JNJ-77242113 matching placebo from Week 0 to Week 16. Participants will cross-over to receive JNJ-77242113 from Week 16 through Week 156.

Group Type EXPERIMENTAL

JNJ-77242113

Intervention Type DRUG

JNJ-77242113 will be administered orally.

Placebo

Intervention Type DRUG

Placebo will be administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ-77242113

JNJ-77242113 will be administered orally.

Intervention Type DRUG

Placebo

Placebo will be administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion Criteria

* Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
* Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Dermatology Specialists

Phoenix, Arizona, United States

Site Status

Johnson Dermatology

Fort Smith, Arkansas, United States

Site Status

First OC Dermatology

Fountain Valley, California, United States

Site Status

Center for Dermatology Clinical Research

Fremont, California, United States

Site Status

Integrative Skin Science and Research

Sacramento, California, United States

Site Status

Rady Childrens Hospital San Diego

San Diego, California, United States

Site Status

Southern California Dermatology

Santa Ana, California, United States

Site Status

Clinical Science Institute

Santa Monica, California, United States

Site Status

Bioclinical Research Alliance Inc.

Miami, Florida, United States

Site Status

Ziaderm Research LLC

North Miami Beach, Florida, United States

Site Status

Forcare Clinical Research Inc

Tampa, Florida, United States

Site Status

Skin Care Physicians of Georgia

Macon, Georgia, United States

Site Status

Arlington Dermatology

Rolling Meadows, Illinois, United States

Site Status

Northshore Medical Group

Skokie, Illinois, United States

Site Status

Dundee Dermatology

West Dundee, Illinois, United States

Site Status

Dawes Fretzin Clinical Research Group LLC

Indianapolis, Indiana, United States

Site Status

Indiana Clinical Trial Center

Plainfield, Indiana, United States

Site Status

Qualmedica Research

Owensboro, Kentucky, United States

Site Status

Dermatology and Advanced Aesthetics

Lake Charles, Louisiana, United States

Site Status

Allcutis Research

Beverly, Massachusetts, United States

Site Status

Michigan Center of Medical Research

Clarkston, Michigan, United States

Site Status

Minnesota Clinical Study Center

New Brighton, Minnesota, United States

Site Status

Skin Specialists

Omaha, Nebraska, United States

Site Status

Allcutis Research

Portsmouth, New Hampshire, United States

Site Status

Schweiger Dermatology Group

East Windsor, New Jersey, United States

Site Status

Icahn School of Medicine at Mt. Sinai

New York, New York, United States

Site Status

Wilmington Dermatology Center

Wilmington, North Carolina, United States

Site Status

Oakview Dermatology

Athens, Ohio, United States

Site Status

Optima Research

Boardman, Ohio, United States

Site Status

Wright State Physicians Health Center

Fairborn, Ohio, United States

Site Status

Central Sooner Research

Oklahoma City, Oklahoma, United States

Site Status

Oregon Medical Research Center

Portland, Oregon, United States

Site Status

Oregon Dermatology and Research Center

Portland, Oregon, United States

Site Status

The Pennsylvania Centre for Dermatology, LLC

Exton, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

Arlington Research Center, Inc.

Arlington, Texas, United States

Site Status

The University of Texas Health Science Center at Houston

Bellaire, Texas, United States

Site Status

Center for Clinical Studies

Houston, Texas, United States

Site Status

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States

Site Status

Center for Clinical Studies

Webster, Texas, United States

Site Status

Springville Dermatology CCT Research

Springville, Utah, United States

Site Status

Virginia Dermatology Skin Cancer Center Pllc

Norfolk, Virginia, United States

Site Status

Frontier Derm Partners CRO, LLC

Mill Creek, Washington, United States

Site Status

Premier Clinical Research

Spokane, Washington, United States

Site Status

ARCIS Salud SRL Aprillus asistencia e investigacion

Buenos Aires, , Argentina

Site Status

Centro Privado de Medicina Familiar

Buenos Aires, , Argentina

Site Status

Derma Internacional S A

Buenos Aires, , Argentina

Site Status

Psoriahue

CABA, , Argentina

Site Status

Centro de Investigaciones Medicas Mar Del Plata

Mar del Plata, , Argentina

Site Status

Instituto De Especialidades De La Salud SRL

Rosario, , Argentina

Site Status

MR Medicina Reumatologica

San Fernando, , Argentina

Site Status

Dr Rodney Sinclair Pty Ltd

East Melbourne, , Australia

Site Status

The Alfred Hospital

Melbourne, , Australia

Site Status

Kingsway Dermatology & Aesthetics

Miranda, , Australia

Site Status

ISHI dermatology

Mitcham, , Australia

Site Status

Royal Melbourne Hospital

Parkville, , Australia

Site Status

Veracity Clinical Research

Woolloongabba, , Australia

Site Status

Dermatology Research Institute Inc

Calgary, Alberta, Canada

Site Status

Rejuvenation Dermatology Clinic Edmonton Downtown

Edmonton, Alberta, Canada

Site Status

Dr. Chih ho Hong Medical

Surrey, British Columbia, Canada

Site Status

Mediprobe Research Inc.

London, Ontario, Canada

Site Status

Dr Wei Jing Loo Medicine Professional Corporation

London, Ontario, Canada

Site Status

Ryan Clinical Research Inc

Newmarket, Ontario, Canada

Site Status

Canadian Dermatology Center

Toronto, Ontario, Canada

Site Status

Toronto Research Centre

Toronto, Ontario, Canada

Site Status

FACET Dermatology

Toronto, Ontario, Canada

Site Status

XLR8 Medical Research

Windsor, Ontario, Canada

Site Status

Innovaderm Research Inc.

Montreal, Quebec, Canada

Site Status

China Japan Friendship Hospital

Beijing, , China

Site Status

Beijing Friendship Hospital Capital Medical University

Beijing, , China

Site Status

Peking University Third Hospital

Beijing, , China

Site Status

The Affiliated Hospital of Bengbu Medical College

Bengbu, , China

Site Status

Hosp. of Chengde Medical University

Chengde, , China

Site Status

Chengdu Second People's Hospital

Chengdu, , China

Site Status

The First Hospital of Jiaxing

Jiaxing, , China

Site Status

Qilu Hospital of Shandong University

Jinan, , China

Site Status

Dermatology Hospital of Jiangxi Province

Nanchang, , China

Site Status

Nanyang First People's Hospital

Nanyang, , China

Site Status

Shanghai skin disease hospital

Shanghai, , China

Site Status

Northeast International Hospital

Shenyang, , China

Site Status

Union Hospital Tongji Medical College of Huazhong University of Science and Technology

Wuhan, , China

Site Status

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, , China

Site Status

Affiliated Hospital of Jiangsu University

Zhenjiang, , China

Site Status

Hopital Prive d'Antony

Antony, , France

Site Status

Centre Hospitalier Victor Dupouy

Argenteuil, , France

Site Status

Fachklinik Bad Bentheim

Bad Bentheim, , Germany

Site Status

Charite - Campus Mitte

Berlin, , Germany

Site Status

Universitatsklinikum Bonn

Bonn, , Germany

Site Status

Klinische Forschung Dresden GmbH

Dresden, , Germany

Site Status

Hautzentrum Dulmen

Dülmen, , Germany

Site Status

Privatpraxis Dr. Hilton & Partner

Düsseldorf, , Germany

Site Status

Universitaetsklinikum Frankfurt

Frankfurt am Main, , Germany

Site Status

Universitaetsklinikum Freiburg

Freiburg im Breisgau, , Germany

Site Status

Derma-Study-Center Friedrichshafen GmbH

Friedrichshafen, , Germany

Site Status

Universitaetsklinikum Heidelberg

Heidelberg, , Germany

Site Status

Hautarztpraxis

Mahlow, , Germany

Site Status

Universitaetsklinikum Muenster

Münster, , Germany

Site Status

Klinikum Oldenburg

Oldenburg, , Germany

Site Status

Hautarztpraxis Mortazawi

Remscheid, , Germany

Site Status

Universitaetsklinik Tuebingen

Tübingen, , Germany

Site Status

Hautarztpraxis

Witten, , Germany

Site Status

CentroDerm GmbH

Wuppertal, , Germany

Site Status

Pecsi Tudomanyegyetem

Borgyogyaszati Klinika, , Hungary

Site Status

Obudai Egeszsegugyi Centrum Kft

Budapest, , Hungary

Site Status

Derma-B Kft

Debrecen, , Hungary

Site Status

Debreceni Egyetem Klinikai Kozpont

Debrecen, , Hungary

Site Status

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Kaposvár, , Hungary

Site Status

SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika

Szeged, , Hungary

Site Status

Allergo-Derm Bakos Kft.

Szolnok, , Hungary

Site Status

Medmare Egeszsegugyi Es Szolgaltato Bt.

Veszprém, , Hungary

Site Status

Azienda Di Rilievo Nazionale E Di Alta Specializzazione

Palermo, , Italy

Site Status

Azienda Ospedaliero Universitaria di Parma

Parma, , Italy

Site Status

Policlinico Tor Vergata

Roma, , Italy

Site Status

Istituto Clinico Humanitas

Rozzano, , Italy

Site Status

Teikyo University Hospital

Itabashi Ku, , Japan

Site Status

Hospital of the University of Occupational and Enviromental Health

Kitakyushu-shi, , Japan

Site Status

Mito Kyodo General Hospital

Mito, , Japan

Site Status

Nagoya City University Hospital

Nagoya, , Japan

Site Status

Kindai University Hospital

Osaka Sayama Shi, , Japan

Site Status

Tohoku University Hospital

Sendai, , Japan

Site Status

Tokyo Medical University Hospital

Shinjuku, , Japan

Site Status

Mie University Hospital

Tsu, , Japan

Site Status

Osteo-Medic s.c A. Racewicz, J Supronik

Bialystok, , Poland

Site Status

Specderm Poznanska sp j

Bialystok, , Poland

Site Status

Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska

Elblag, , Poland

Site Status

Centrum Medyczne dr Rajzer Sp z o o

Krakow, , Poland

Site Status

Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna

Krakow, , Poland

Site Status

Centrum Medyczne Promed

Krakow, , Poland

Site Status

Dermed Centrum Medyczne Sp z o o

Lodz, , Poland

Site Status

Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna

Lodz, , Poland

Site Status

Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C

Osielsko, , Poland

Site Status

SOLUMED Centrum Medyczne

Poznan, , Poland

Site Status

Clinical Research Center sp z o o MEDIC R s k

Poznan, , Poland

Site Status

Dorota Bystrzanowska High-Med. Przychodnia Specjalistyczna

Warsaw, , Poland

Site Status

Klinika Ambroziak Dermatologia

Warsaw, , Poland

Site Status

DERMMEDICA Sp.z o.o.

Wroclaw, , Poland

Site Status

Wro Medica

Wroclaw, , Poland

Site Status

Centrum Medyczne Oporow

Wroclaw, , Poland

Site Status

Korea University Ansan Hospital

Ansan-si, , South Korea

Site Status

Chosun university hospital

Gwangju, , South Korea

Site Status

CHA Bundang Medical Center, CHA University

Gyeonggi-do, , South Korea

Site Status

Hallym University Sacred Heart Hospital

Gyeonggi-do, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Hosp. Univ. Fundacion Alcorcon

Alcorcón, , Spain

Site Status

Hosp. Gral. Univ. Dr. Balmis

Alicante, , Spain

Site Status

Hosp Clinic de Barcelona

Barcelona, , Spain

Site Status

Hosp. de La Santa Creu I Sant Pau

Barcelona, , Spain

Site Status

Hosp. Univ. de Basurto

Bilbao, , Spain

Site Status

Grupo Dermatologico Y Estetico Pedro Jaen

Madrid, , Spain

Site Status

Hosp. Gral. Univ. Gregorio Maranon

Madrid, , Spain

Site Status

Hosp. Univ. Son Espases

Palma de Mallorca, , Spain

Site Status

Hosp. Clinico Univ. de Santiago

Santiago de Compostela, , Spain

Site Status

Hosp. Virgen Macarena

Seville, , Spain

Site Status

Hosp. de Manises

Valencia, , Spain

Site Status

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

National Taiwan University Hospital Hsin Chu Branch

Taoyuan District, , Taiwan

Site Status

Linkou Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Site Status

Hacettepe University Medical Faculty

Ankara, , Turkey (Türkiye)

Site Status

Gazi University Medical Faculty

Ankara, , Turkey (Türkiye)

Site Status

Erciyes University Medical Faculty

Kayseri, , Turkey (Türkiye)

Site Status

Ondokuz Mayis University

Samsun, , Turkey (Türkiye)

Site Status

London North West University Healthcare NHS Trust

Harrow, , United Kingdom

Site Status

Guys and St Thomas NHS Foundation Trust

London, , United Kingdom

Site Status

Royal Berkshire Hospital

Reading, , United Kingdom

Site Status

Salford Royal Hospital

Salford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Canada China France Germany Hungary Italy Japan Poland South Korea Spain Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, Shi Y, Wang WH, Toth DP, Miller-Kassamali M, Cafone J, Jiang J, Li S, DeKlotz CMC, Nunes F, Lebwohl MG. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med. 2025 Nov 6;393(18):1784-1795. doi: 10.1056/NEJMoa2504187.

Reference Type DERIVED
PMID: 41191940 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

77242113PSO3001

Identifier Type: OTHER

Identifier Source: secondary_id

2023-505120-59-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

77242113PSO3001

Identifier Type: -

Identifier Source: org_study_id